Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dividend Distribution
confidence 95%
filed 2026-06-23
Item 7.01
Accenture announced a $2 billion increase to its fiscal year 2026 share repurchase program, bringing total planned repurchases to $7.5 billion (a 62% increase year-over-year). The news release explicitly states this represents a return of capital to shareholders, with total planned shareholder returns for FY2026 expected to reach $11.5 billion including dividends and repurchases. Share repurchases are a form of capital distribution to shareholders and fall within the dividend_distribution category.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-23
Item 7.01
ASP Isotopes announced that Tetra4 (a Renergen subsidiary) has entered into its first take-or-pay contract for helium supply at greater than $600/MCF with an Asian industrial gases company, representing approximately 15% of Phase 1 nameplate capacity. This is a material commercial contract milestone for the Virginia Gas Project's Phase 1 operations targeted for Q3 2026. While this could be characterized as a material contract or partnership, it does not fit the specific categories of M&A activity, debt issuance, or other defined financial events—it is a significant operational and commercial development that would affect investor assessment of the company's revenue prospects and project viability.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-23
Item 2.02
This is a press release announcing full-year fiscal 2026 financial results for CEA Industries Inc., disclosing net income of $115.2 million ($2.52 per diluted share), digital asset holdings of 515,544 BNB tokens valued at approximately $317.3 million, and $7.9 million in airdrop income. The disclosure is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The material financial results and strategic transformation details would affect a reasonable investor's assessment of the company.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
Stockholders voted at the Annual Meeting on four proposals: election of three Class III directors (Friesner, Kapeller-Libermann, Sender), advisory vote on executive compensation, approval of a 2022 Equity Incentive Plan amendment increasing the share reserve by 3,000,000 shares, and ratification of KPMG LLP as independent auditor. Detailed voting results including FOR, AGAINST, ABSTAINING, and BROKER NON-VOTES tallies were disclosed for each proposal.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-06-23
EX-99.1
This exhibit is a Securities Purchase Agreement for an unregistered private placement of up to $30,000,000 of Ordinary Shares at USD 0.6 per share to non-US persons under Regulation S and Section 4(a)(2) exemptions. The agreement explicitly states the Company is relying on exemptions from securities registration and the Purchasers are "non-US persons" acquiring securities in a private placement. This is a material dilutive issuance of equity securities outside a registered offering, typical of PIPE or private placement activity that would materially affect shareholder equity and voting power.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-23
Dreamland Limited entered into a securities purchase agreement on June 22, 2026, to issue 320,000 Class A ordinary shares at US$3.75 per share for aggregate gross proceeds of US$1,200,000. The shares were issued in an unregistered offshore transaction under Regulation S to a non-U.S. person (Imperial Vision Fund SPC Series 1 SP), with transfer restrictions and restrictive legends. This is a classic private placement of unregistered equity securities, which is material to investors as it represents dilution and a capital raise.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-06-23
The filing discloses announcement of fiscal year 2026 financial results for the period ended March 31, 2026, to be released on June 29, 2026, with a management conference call scheduled for June 30, 2026. The press release explicitly states "Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2026 Financial Results" and "Financials for Fiscal Year 2026 Ended March 31, 2026 will be released on Monday, June 29, 2026." This is a standard earnings release announcement under Item 2.02 and Item 7.01.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-23
The filing discloses the appointment of Lukas Lutz as an independent director and member of the Nominating and Corporate Governance Committee, effective June 18, 2026, replacing Brian Nelson. The appointment includes a grant of 10,000 RSUs with staggered vesting and standard director compensation, which are material governance changes affecting board composition and leadership structure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-23
Item 8.01
The filing announces adoption of Microbot's LIBERTY Endovascular Robotic System by a Pennsylvania health system, expanding the company's geographic footprint to seven states and demonstrating continued commercialization progress. This is a material operational/commercial milestone reflecting successful market penetration and customer adoption of the company's primary product, but does not fit the specific categories of earnings release, M&A activity, or other named event types.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-23
The filing discloses the appointment of Dr. Corazon (Corsee) Sanders to the Board of Directors as a Class III director effective June 17, 2026, and her concurrent appointment to the Audit Committee. The principal disclosed action is a person taking a role. Dr. Sanders is a highly experienced biotechnology executive with 30+ years of leadership at major firms (Genentech/Roche, Juno/Celgene/BMS) and currently serves on multiple public company boards, making her appointment material to investors assessing the company's governance and strategic direction.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-23
EX-99.1
The exhibit announces that TechCreate has filed an appeal to the NYSE American Listing Qualifications Panel in response to a Staff determination to commence delisting proceedings. The Company received notice on June 12, 2026 that NYSE American Staff determined to commence delisting proceedings based on an SEC trading suspension on February 2, 2026 related to alleged share manipulation. This is a direct disclosure of delisting risk and proceedings initiated by the exchange, which is material to investors' assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-06-23
The 6-K discloses a reverse stock split (1-for-2 consolidation) effective June 29, 2026, explicitly stated as undertaken "to regain compliance with Nasdaq Listing Rule 5550(a)(2)." This indicates the company had fallen below the minimum bid price requirement and faced delisting risk. The reverse split is a direct response to a continued listing rule violation, making this a delisting_risk disclosure.
View raw filing on EDGAR →
6-K
Other material
confidence 65%
filed 2026-06-23
The 6-K discloses two related transactions by Chairman Choo Chee Kong: (1) an offer to acquire up to 200,000 Company shares from independent shareholders via private purchase agreement, and (2) a S$300,000 investment by his wholly-owned EP Capital Inc. into LongevityBank (a Company subsidiary), increasing EP Capital's stake from 6.4% to 12.0%. While these transactions involve significant capital deployment and potential changes to shareholding structure and subsidiary ownership, they do not fit neatly into standard event categories—they are neither a formal M&A transaction (no merger or acquisition of the Company itself), nor a simple insider share purchase, nor a capital raise by the Company. The disclosure is material because it signals insider confidence and capital commitment, but the event's nature—insider accumulation and subsidiary investment—is ambiguous enough to warrant the catch-all category.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-06-23
EX-99.1
QMMM received a Staff Delisting Determination from Nasdaq on June 17, 2026, notifying the Company that Nasdaq has determined to delist its securities pursuant to Listing Rule IM-5101-4, with an independent basis cited under Rule 5250(c)(1) for delay in filing Form 20-F. The Company intends to appeal and request a hearing before the Nasdaq Hearings Panel, but there is no assurance the Panel will approve the compliance plan. This is a direct delisting notice meeting the definition of delisting_risk.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-23
The filing discloses an unregistered private placement of 201,500 restricted shares of common stock to five private investors at $2.75 per share, completed in March and April 2026 and closed on June 23, 2026. Items 1.01 and 3.02 explicitly describe the issuance and claim exemptions under Section 4(a)(2) and Regulation D, which are hallmarks of a dilutive equity issuance. This represents a material capital-raising event that would affect shareholder ownership and the total mix of information available to investors.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-23
Safe Pro Group announced a $1.3 million U.S. Government subcontract award to integrate its AI-powered threat detection technology into unmanned ground vehicles. This is a material operational/commercial milestone—a significant government contract win—but does not fit neatly into predefined categories like earnings release, M&A, or debt issuance. The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) and represents a material business development event that would affect a reasonable investor's assessment of the company's revenue prospects and market position.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-23
EX-99.1
Alps Group Inc announced a Research and Collaboration Agreement with Dr. Kong Wai Mun to launch a patient-derived organoid (PDO) program for personalized cancer care in Southeast Asia. This represents a material expansion into precision oncology testing and a new business line, with the company targeting Malaysia's first clinically validated PDO platform. The announcement describes a strategic operational initiative involving new clinical partnerships (six major oncology centers identified), regulatory pathways (MREC ethics approval and MDA registration), and a national PDO biobank, which would affect a reasonable investor's assessment of the company's growth strategy and market positioning.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-06-23
The filing discloses a Nasdaq Letter of Reprimand for violation of Listing Rule 5635(c) regarding shareholder approval of equity awards issued in excess of the 2019 Stock and Incentive Compensation Plan. While the Company's shares remain listed (delisting was not imposed), the violation and regulatory sanction constitute a material governance event involving shareholder approval requirements and executive compensation matters. The Company self-reported the inadvertent issuance of "Excess Awards" and obtained subsequent shareholder ratification, but the regulatory finding of non-compliance is material to investors assessing governance quality and compliance risk.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-23
The filing discloses the appointment of Kevin Miller as Executive Vice President, Chief Financial Officer and Treasurer, effective June 1, 2026, with an employment agreement dated June 18, 2026. While the agreement includes detailed compensation terms (base salary of $430,000, bonus eligibility, and equity awards), the principal disclosed action is the appointment of a named executive officer to a C-suite position. This is material to investors as it represents a significant leadership change in the company's financial management.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-23
The filing discloses entry into securities purchase agreements under Item 1.01 for the issuance of up to 43.3 billion units (each consisting of one share of common stock and one warrant) at $0.015 per unit for approximately $650 million in gross proceeds. An initial closing on June 22, 2026 resulted in issuance of 1.8 billion shares of common stock (900 million shares plus 900 million from warrant exercise). This is a classic dilutive private placement of equity securities to non-U.S. investors, materially diluting existing shareholders and raising substantial capital.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 92%
filed 2026-06-23
The 6-K discloses results of an Extraordinary General Meeting held on June 22, 2026, where shareholders approved two resolutions: (1) re-designation of 1,000,000 issued preferred shares as Series A preferred shares and authorization of 49,000,000 additional preferred shares with rights to be determined by Directors, and (2) adoption of a Third Amended and Restated Memorandum and Articles of Association. This is a classic shareholder vote result disclosure. The Share Redesignation and Share Capital Changes are material to investors as they alter the company's authorized capital structure and preferred share terms.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-23
Sharplink entered into a securities purchase agreement on June 22, 2026, to sell 10,013,351 shares of common stock at $7.49 per share (approximately $75 million gross proceeds) plus 10,013,351 warrants with an exercise price of $8.15 per share. This is a registered direct offering disclosed under Item 1.01 (Entry into a Material Definitive Agreement), representing a dilutive equity issuance to raise capital for cryptocurrency acquisition and general corporate purposes. The transaction is material to investors as it significantly increases share count and dilution.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-06-23
The filing discloses that on June 23, 2026, the Company's insiders deposited a $125,000 contribution to extend the business combination deadline by one month (the fourth such monthly extension), pursuant to shareholder approval at an extraordinary general meeting on March 18, 2026. This is a governance matter involving amendment of the Company's memorandum and articles of association and insider funding arrangements to extend the SPAC's business combination deadline, which materially affects the timeline and structure of the proposed transaction.
View raw filing on EDGAR →
8-K
Restatement
confidence 98%
filed 2026-06-23
The filing discloses under Item 4.02 that the Board concluded on June 23, 2026 that previously issued unaudited condensed consolidated financial statements for three interim periods in 2024 (Q1, Q2, and Q3) should no longer be relied upon due to multiple accounting errors including misclassifications of client funds, related party advances, subscription receivables, intercompany eliminations, omitted share issuances, and foreign currency translation errors. The Company identified material weaknesses in internal controls and restated the affected interim periods as comparative information in amended 2025 quarterly reports. This is a clear financial restatement disclosure under Item 4.02.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-23
Wayne Tupuola, the President and CEO, took a three-month leave of absence for health reasons on June 16, 2026, and the Board appointed Ann Tewari, Executive Vice President of Global Operations and Strategy, as Interim President. While the filing discloses both a departure (Tupuola's leave) and an appointment (Tewari's interim role), the principal disclosed action centers on the appointment of interim leadership to fill the CEO vacancy during Tupuola's absence. This is material as it affects the registrant's executive leadership structure and investor assessment of operational continuity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-23
The filing discloses an unregistered sale of 356 Series A Convertible Preferred Shares to TriCore Foundation, LLC for $320,400 on June 17, 2026, made in reliance on Section 4(a)(2) of the Securities Act. This is a classic dilutive issuance under Item 3.02, involving convertible securities sold to a related party without registration. The transaction is material as it represents new equity capital raised and potential dilution to existing shareholders upon conversion.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-06-23
The Company entered into a Loan and Security Agreement on June 18, 2026, creating a new $2.5 million secured term loan obligation with a 10% interest rate maturing June 17, 2027. This is a material creation of direct financial obligation. The Company explicitly states it intends to use proceeds to repay an existing credit facility, indicating this is a refinancing event. The security interest granted in all assets and restrictive covenants (restrictions on incurring additional indebtedness, liens, and business changes) are typical debt issuance terms.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-06-23
The filing discloses entry into a definitive Agreement and Plan of Merger (Item 1.01) whereby Black Pearl Equities will acquire all outstanding shares of Selectis Health for $5.75 per share in cash through a tender offer followed by a short-form merger. This is a material acquisition transaction with clear economic terms, board approval, and no financing contingencies, representing a change of control of the company.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-06-23
The filing discloses that on June 23, 2026, the Audit Committee dismissed BCRG as the independent registered public accounting firm and appointed Simon & Edward LLP as the new auditor, effective after BCRG's attest business was acquired by S&E on June 15, 2026. This is a clear auditor change under Item 4.01. The materiality is heightened by the disclosure that BCRG's prior audit reports contained an explanatory paragraph indicating substantial doubt about the Company's ability to continue as a going concern.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-23
The Board authorized engagement of specialized litigation counsel to pursue legal remedies against former management and service providers for alleged self-dealing, unauthorized dilutive equity issuances, and improper debt instruments. The disclosure explicitly identifies allegations of misconduct, directs counsel to prepare formal demands for restitution and potential court complaints, and seeks recovery of assets and cancellation of securities—hallmarks of material litigation activity that would affect investor assessment of the company's governance and financial position.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-23
Item 5.02
Robert Brackenbury was appointed to the Board of Directors of Athene Holding Ltd. as an independent director effective June 23, 2026. Brackenbury brings extensive experience as Deputy Chief Investment Officer of the State of Michigan Retirement System, where he oversaw $170 billion in assets, and brings expertise in retirement services and institutional investment management.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-23
Item 8.01
The Company engaged CBRE's National Retail Partners on June 19, 2026 to "list and market for sale thirty-five of those fifty-nine properties as a portfolio sale transaction." This represents a material disposition of approximately 59% of the Company's real estate portfolio. Although the transaction is contemplated rather than completed, the engagement of a major broker to market a substantial portfolio for sale constitutes a material M&A/disposition activity that would affect a reasonable investor's assessment of the registrant's strategic direction and asset base.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-23
Item 5.02
The filing discloses the appointment of Ron Philip to the Board of Directors of Avalo Therapeutics, effective June 23, 2026. The principal disclosed action is a person taking a role as director and committee member. While the disclosure includes compensatory arrangements (stock option grant of 40,200 shares), the core event is the appointment itself, making exec_appointment the most salient classification. Board appointments by experienced executives (Philip's background includes CEO roles at Spark Therapeutics and Orbital Therapeutics) are material to investors.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 75%
filed 2026-06-23
Item 8.01
The filing explicitly states "This current report on Form 8-K relates to a distribution made to holders of the Certificates issued by the Select Notes Trust LT 2003-1." This is a distribution to certificate holders of a structured trust, which constitutes a dividend or distribution event. The materiality is supported by the fact that the trust is disclosing this distribution activity to the market, and distributions to security holders are typically material to investors.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 75%
filed 2026-06-23
Item 8.01
The filing explicitly states it "relates to a distribution made to holders of the Certificates issued by the Select Notes Trust LT 2003-2." This is a distribution to security holders of a structured trust vehicle. While the disclosure is largely boilerplate regarding underlying issuer reporting requirements, the core event triggering the 8-K is the distribution itself, which falls under dividend_distribution. The materiality is marked true because distributions to certificate holders are material to investors in the trust.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 75%
filed 2026-06-23
Item 8.01
The filing explicitly states "This current report on Form 8-K relates to a distribution made to holders of the Certificates issued by the Select Notes Trust LT 2003-3." This is a distribution to certificate holders, which constitutes a dividend or distribution event. While the prose is largely boilerplate disclosure about underlying security issuers and SEC reporting requirements, the core event disclosed is the distribution itself, making this a dividend_distribution classification.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 75%
filed 2026-06-23
Item 8.01
The filing explicitly states "This current report on Form 8-K relates to a distribution made to holders of the Certificates issued by the Select Notes Trust LT 2003-4." This is a distribution to certificate holders, which constitutes a dividend or distribution event. While the disclosure is largely boilerplate regarding underlying security reporting requirements, the core event triggering the 8-K is the distribution itself, making this a dividend_distribution classification.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 75%
filed 2026-06-23
Item 8.01
The filing explicitly states "This current report on Form 8-K relates to a distribution made to holders of the Certificates issued by the Select Notes Trust LT 2003-5." This is a distribution to certificate holders, which constitutes a dividend or distribution event. While the disclosure is largely boilerplate regarding underlying security reporting requirements, the core event disclosed is the distribution itself, making this a dividend_distribution classification.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-06-23
This 8-K discloses the entry into an underwriting agreement for the issuance of mortgage pass-through certificates (Series 2026-5C10) with an aggregate initial principal amount of $475.2 million in publicly offered certificates plus $71 million in privately offered certificates. The filing describes the creation of a new direct financial obligation through the issuance of debt securities backed by a pool of commercial mortgage loans, which is the hallmark of a debt issuance event under Item 8.01 (Other Events).
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-23
EX-99.1
Trinity Biotech announced the launch of Trinovium, a new subsidiary focused on advanced liquid cooling solutions for AI data centers. This represents a material strategic expansion into a new market segment (projected to grow from $4 billion in 2026 to $27 billion by 2033) leveraging existing manufacturing capacity. While not a traditional M&A transaction, the creation of a dedicated subsidiary with a distinct business focus and capital-efficient entry into a high-growth market constitutes a significant operational and strategic initiative that would affect a reasonable investor's assessment of the company's growth prospects and business diversification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-23
Item 5.02
Cal-Maine Foods appointed two independent directors, Haley R. Fisackerly and Michael J. Highfield, to its Board of Directors effective June 23, 2026, expanding the Board from eight to ten directors. The new directors bring expertise in operations, infrastructure, finance, capital markets, and organizational leadership, and were assigned to three Board committees.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-06-23
Item 8.01
News Corporation discloses daily buy-back notifications under its US$1 billion repurchase program authorized as of July 15, 2025. The Item 8.01 disclosure reports that the Company has purchased approximately US$323.8 million worth of Class A and Class B shares to date, with recent transactions totaling US$210 million across both classes. Share repurchase programs are a form of capital return to shareholders and fall within the dividend_distribution taxonomy as a return of capital, distinct from operational or financial events. The materiality is evident from the scale (US$1 billion authorization, US$323.8 million deployed) and the explicit statement that the repurchase is intended "to enhance shareholder value."
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-06-23
Item 1.01
AMASS Brands invested $1,535,000 (after amendment) in AfterDream via a SAFE agreement, which is a form of convertible equity instrument that will convert into shares upon future triggering events (Equity Financing, Liquidity Event, or Dissolution Event). While the SAFE is technically an investment by AMASS rather than an issuance by AMASS, the structure and mechanics—conversion into equity at a valuation cap with dilutive potential—align with the dilutive_issuance category's focus on equity capital raises. However, this could also be classified as a material investment or financial transaction under financial_other if viewed as AMASS deploying capital rather than raising it. The Item 1.01 designation and the material dollar amount ($1.535M) support materiality.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-23
Item 1.01
Upwork entered into a $150 million secured revolving credit facility with Bank of America as administrative agent on June 23, 2026, with an option to increase by up to $50 million. The facility has customary covenants, interest rate terms, and a three-year maturity.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-23
Item 2.02
Sunbelt Rentals disclosed financial results for fiscal fourth quarter and full-year ended April 30, 2026, including total revenue of $11.154 billion, net income of $1.325 billion, and adjusted EBITDA of $4.677 billion, along with forward guidance for fiscal 2027 and capital allocation decisions totaling $1.877 billion in dividends and buybacks.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-23
Item 1.01
Backblaze entered into a Master Strategic Agreement with CoreWeave effective June 16, 2026, representing a material multi-year commercial arrangement valued at approximately $335 million over five to seven years. The agreement establishes a significant strategic partnership for HDD-based storage capacity supporting CoreWeave's AI infrastructure and includes equity consideration through warrant issuance of 4.2 million shares.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
This 8-K Item 5.07 discloses the final voting results from GeneDx Holdings Corp.'s Annual Meeting of Stockholders held on June 18, 2026. The filing presents detailed tabulations of votes cast on four proposals: election of a Class II director (Katherine Stueland), ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on the frequency of future compensation votes. All proposals were approved. This is a standard shareholder vote results disclosure required under Item 5.07.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 98%
filed 2026-06-23
EX-99.1
This exhibit discloses the results of Klarna Group plc's 2026 Annual General Meeting held on 22 June 2026, with detailed voting tallies for all 12 resolutions including re-appointment of directors (Niclas Neglén, Andrew Reed, Mateusz Staniszewski, Markus Villig), re-appointment of auditors (Ernst & Young LLP), and approval of remuneration policies. All resolutions passed at or above 99% of votes cast, representing shareholder governance decisions that are material to investors' assessment of board composition and auditor continuity.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-06-23
EX-99.1
This is a quarterly earnings press release disclosing ICON's Q1 2026 financial results, including revenue of $2,034.0 million, GAAP net income of $104.8 million ($1.36 diluted EPS), adjusted EBITDA of $317.7 million, and reaffirmed full-year 2026 guidance. The document contains consolidated statements of operations, balance sheets, and cash flows for the three months ended March 31, 2026, along with management commentary from CEO Barry Balfe. This is a material event affecting investor assessment of the registrant's financial performance and outlook.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-23
Item 3.02
The Fund sold 341,423 Class I common shares for $9.2 million during June 2026 in an unregistered offering exempt under Section 4(a)(2) and Regulation S, materially diluting existing shareholders' ownership percentages.
View raw filing on EDGAR →